title: Microbiota abnormalities in inflammatory airway diseases - Potential for therapy.
abstract: Increasingly the development of novel therapeutic strategies is taking into consideration the contribution of the intestinal microbiota to health and disease. Dysbiosis of the microbial communities colonizing the human intestinal tract has been described for a variety of chronic diseases, such as inflammatory bowel disease, obesity and asthma. In particular, reduction of several so-called probiotic species including Lactobacilli and Bifidobacteria that are generally considered to be beneficial, as well as an outgrowth of potentially pathogenic bacteria is often reported. Thus a tempting therapeutic approach is to shape the constituents of the microbiota in an attempt to restore the microbial balance towards the growth of 'health-promoting' bacterial species. A twist to this scenario is the recent discovery that the respiratory tract also harbors a microbiota under steady-state conditions. Investigators have shown that the microbial composition of the airway flora is different between healthy lungs and those with chronic lung diseases, such as asthma, chronic obstructive pulmonary disease as well as cystic fibrosis. This is an emerging field, and thus far there is very limited data showing a direct contribution of the airway microbiota to the onset and progression of disease. However, should future studies provide such evidence, the airway microbiota might soon join the intestinal microbiota as a target for therapeutic intervention. In this review, we highlight the major advances that have been made describing the microbiota in chronic lung disease and discuss current and future approaches concerning manipulation of the microbiota for the treatment and prevention of disease.
authors: Faculty of Biology and Medicine, University of Lausanne, Service de Pneumologie, CHUV, Lausanne, Switzerland.
authors: Eva S
authors: ES
authors: Gollwitzer
authors: Faculty of Biology and Medicine, University of Lausanne, Service de Pneumologie, CHUV, Lausanne, Switzerland. Electronic address: benjamin.marsland@chuv.ch.
authors: Benjamin J
authors: BJ
authors: Marsland
mesh_terms: D064806:Dysbiosis / Q000150:complications / Q000178:diet therapy*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000178:diet therapy* / Q000382:microbiology*; D008171:Lung Diseases / Q000150:complications / Q000178:diet therapy* / Q000382:microbiology*; D056692:Prebiotics; D019936:Probiotics / Q000627:therapeutic use*; D012137:Respiratory System / Q000187:drug effects / Q000382:microbiology; D058616:Synbiotics
chemical_list: D056692:Prebiotics
keywords: Airways; BOS; CF; COPD; Chronic lung disease; FMT; IBD; Intestinal tract; Microbiome; Microbiota; Probiotics; bronchiolitis obliterans syndrome; chronic obstructive pulmonary disease; cystic fibrosis; fecal microbiota transplantation; inflammatory bowel disease